CoChat

Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers

Pillow, Thomas H., Schutten, Melissa, Yu, Shang-Fan, Ohri, Rachana, Sadowsky, Jack, Poon, Kirsten Achilles, Solis, Willy, Zhong, Fiona, Del Rosario, Geoffrey, Go, Mary Ann T., Lau, Jeffrey, Yee, Sharon, He, Jintang, Liu, Luna, Ng, Carl, Xu, Keyang, Leipold, Douglas D., Kamath, Amrita V., Zhang, Donglu, Masterson, Luke, Gregson, Stephen J., Howard, Philip W., Fang, Fan, Chen, Jinhua, Gunzner-Toste, Janet, Kozak, Katherine K., Spencer, Susan, Polakis, Paul, Polson, Andrew G., Flygare, John A., Junutula, Jagath R. · 2017 · Molecular Cancer Therapeutics
Cited by 72

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody–drug conjugates (ADCs). ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker. Both the chemical linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC. This novel disulfide ADC was compared with a conjugate containing the same PBD drug, but attached to the antibody via a peptide linker. Both ADCs had similar efficacy in mice bearing human tumor xenografts. Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC. Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equivalent efficacy and improved safety. Mol Cancer Ther; 16(5); 871–8. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-16-0641

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 72

Metadata

Authors
Pillow, T. H., Schutten, M., Yu, S.-F., Ohri, R., Sadowsky, J., Poon, K. A., Solis, W., Zhong, F., Del Rosario, G., Go, M. A. T., Lau, J., Yee, S., He, J., Liu, L., Ng, C., Xu, K., Leipold, D. D., Kamath, A. V., Zhang, D., Masterson, L., Gregson, S. J., Howard, P. W., Fang, F., Chen, J., Gunzner-Toste, J., Kozak, K. K., Spencer, S., Polakis, P., Polson, A. G., Flygare, J. A., & Junutula, J. R.
Venue
Molecular Cancer Therapeutics
Published
2017-05-01
Volume
16
Issue
5
Pages
871-878
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2591098696
Cited by
72
References
1
FWCI
4.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0641
The paper
Pillow, T. H., Schutten, M., Yu, S.-F., Ohri, R., Sadowsky, J., Poon, K. A., Solis, W., Zhong, F., Del Rosario, G., Go, M. A. T., Lau, J., Yee, S., He, J., Liu, L., Ng, C., Xu, K., Leipold, D. D., Kamath, A. V., Zhang, D., . . . Junutula, J. R. (2017). Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0641

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.